ZIOPHARM Oncology (ZIOP) Has Fallen 47% in Last One Year, Underperforms Market

If you are looking for the best ideas for your portfolio you may want to consider some of Miller Value Partners top stock picks. Miller Value Partners, an investment management firm, is bullish on Ziopharm Oncology Inc (NASDAQ:ZIOP) stock. In its Opportunity Equity Q2 2019 investor letter – you can download a copy here – the firm discussed its investment thesis on Ziopharm Oncology Inc (NASDAQ:ZIOP) stock. Ziopharm Oncology Inc (NASDAQ:ZIOP) is a biotechnology company.

On July 22, 2019, Miller Value Partners had released its Opportunity Equity Q2 2019 investor letter. The investment firm said that Ziopharm Oncology Inc (NASDAQ:ZIOP) was one of the biggest contributors to its performance in Q2 2019. Ziopharm Oncology Inc (NASDAQ:ZIOP) stock has posted a return of -46.5% in the trailing one year period, underperforming fund’s benchmark the S&P 500 Index which returned 15.1% in the same period. This suggests that the investment firm was wrong in its decision. On a year-to-date basis, Ziopharm Oncology Inc (NASDAQ:ZIOP) stock has fallen by 48.1%.

Miller Value Partners Opportunity Equity Fund posted a return of 1.15% in the second quarter of 2019, underperforming fund’s benchmark the S&P 500 Index which returned 4.3% in the same period. Let’s take a look at comments made by Miller Value Partners about Ziopharm Oncology Inc (NASDAQ:ZIOP) stock in the Q2 2019 investor letter.

“Ziopharm Oncology Inc. (ZIOP) increased 51.4% over the quarter. The company announced an exclusive licensing agreement with the National Cancer Institute for intellectual property for the development and commercialization of cell therapies for cancer. Under the agreement, Ziopharm will have the rights to two groups of technologies for use with its “Sleeping Beauty” platform, including T-cell receptors, as well as manufacturing methods and processes to generate large numbers of modified T-cells. This was followed up by the FDA approving the commencement of a Phase I trial evaluating SB-TCR-T cell therapy in solid tumor. The trial will be conducted by the National Cancer Institute (NCI) as part of a cooperative research and development agreement with ZIOP. The company also presented new interim analyses of clinical data from two ongoing sub-studies in its controlled IL-12 platform for the treatment of recurrent or progressive glioblastoma in adults. The company filed a mixed securities shelf with a maximum offering price of $100m.”

Easiest Md/PhD Programs to Get Into


In Q1 2020, the number of bullish hedge fund positions on Ziopharm Oncology Inc (NASDAQ:ZIOP) stock decreased by about 7% from the previous quarter (see the chart here), so a number of other hedge fund managers don’t seem to agree with Ziopharm’s growth potential. Our calculations showed that Ziopharm Oncology Inc (NASDAQ:ZIOP) isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, legal marijuana is one of the fastest growing industries right now, so we are checking out stock pitches like “the Starbucks of cannabis” to identify the next tenbagger. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. Hedge fund sentiment towards Tesla reached its all time high at the end of 2019 and Tesla shares more than tripled this year. We are trying to identify other EV revolution winners, so if you have any good ideas send us an email. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.